Quantifying iron levels in the YAC128 mouse model of Huntington's Disease

Quantifying iron levels in the YAC128 mouse model of Huntington's Disease

Show other versions (1)

Huntington's Disease (HD) is one of many neurodegenerative diseases with reported alterations in brain iron homeostasis. Many neurodegenerative diseases exist which are characterized by brain iron accumulation. Whether elevated brain iron occurs in HD, and whether it plays a significant contrib...

Full description

Bibliographic Details
Main Author:	Muller, Michelle
Language:	English
Published:	University of British Columbia 2014
Online Access:	http://hdl.handle.net/2429/46559

Similar Items

Quantifying iron levels in the YAC128 mouse model of Huntington's Disease
by: Muller, Michelle
Published: (2014)

The role of caspase-2 in the progression of Huntington disease in the YAC128 mouse
by: Carroll, Jeffrey Bryan
Published: (2010)

The role of caspase-2 in the progression of Huntington disease in the YAC128 mouse
by: Carroll, Jeffrey Bryan
Published: (2010)

The role of caspase-2 in the progression of Huntington disease in the YAC128 mouse
by: Carroll, Jeffrey Bryan
Published: (2010)

Assessment of novel therapeutic approaches in the YAC128 mouse model of Huntington disease
by: Pouladi, Mahmoud A.
Published: (2010)

Assessment of novel therapeutic approaches in the YAC128 mouse model of Huntington disease
by: Pouladi, Mahmoud A.
Published: (2010)

Assessment of novel therapeutic approaches in the YAC128 mouse model of Huntington disease
by: Pouladi, Mahmoud A.
Published: (2010)

Levels of mutant huntingtin influence the phenotypic severity of Huntington disease in YAC128 mouse models
by: Rona K. Graham, et al.
Published: (2006-02-01)

Impact of caspase-6 modulation on Huntington disease phenotypes in the YAC128 mouse model
by: Ladha, Safia
Published: (2016)

Altered adult hippocampal neurogenesis in the YAC128 transgenic mouse model of Huntington disease
by: Jessica M. Simpson, et al.
Published: (2011-02-01)

Striosome-matrix pathology and motor deficits in the YAC128 mouse model of Huntington's disease
by: Collene Lawhorn, et al.
Published: (2008-12-01)

Altered Adult Hippocampal Structural and Functional Plasticity in the YAC128 Transgenic Mouse Model of Huntington Disease
by: Simpson, Jessica M.
Published: (2013)

Age-dependent neurovascular abnormalities and altered microglial morphology in the YAC128 mouse model of Huntington disease
by: Sonia Franciosi, et al.
Published: (2012-01-01)

Palmitoylation and function of glial glutamate transporter-1 is reduced in the YAC128 mouse model of Huntington disease
by: Kun Huang, et al.
Published: (2010-10-01)

Natural history of disease in the YAC128 mouse reveals a discrete signature of pathology in Huntington disease
by: Jeffrey B. Carroll, et al.
Published: (2011-07-01)

Protection by dietary restriction in the YAC128 mouse model of Huntington's disease: Relation to genes regulating histone acetylation and HTT
by: Cesar L. Moreno, et al.
Published: (2016-01-01)

Generation and characterization of embryonic stem cell lines derived from the YAC128 mouse model of Huntington disease.
by: Thiele, Jenny
Published: (2010)

Generation and characterization of embryonic stem cell lines derived from the YAC128 mouse model of Huntington disease.
by: Thiele, Jenny
Published: (2010)

Generation and characterization of embryonic stem cell lines derived from the YAC128 mouse model of Huntington disease.
by: Thiele, Jenny
Published: (2010)

Age-dependent alterations in the cortical entrainment of subthalamic nucleus neurons in the YAC128 mouse model of Huntington's disease
by: Joshua W. Callahan, et al.
Published: (2015-06-01)

Phenotypic abnormalities in the YAC128 mouse model of Huntington disease are penetrant on multiple genetic backgrounds and modulated by strain
by: Jeremy M. Van Raamsdonk, et al.
Published: (2007-04-01)

The effects of environmental and microbiota manipulation on myelination in the YAC128 and BACHD models of Huntington disease
by: Radulescu, Carola Izabela
Published: (2017)

Characterization and use of the YAC128 mouse model of HD
by: Slow, Elizabeth Jane
Published: (2009)

NP03, a novel low-dose lithium formulation, is neuroprotective in the YAC128 mouse model of Huntington disease
by: Mahmoud A. Pouladi, et al.
Published: (2012-12-01)

Efficacy of fumaric acid esters in the R6/2 and YAC128 models of Huntington's disease.
by: Gisa Ellrichmann, et al.
Published: (2011-01-01)

Antidepressant Effects of Probucol on Early-Symptomatic YAC128 Transgenic Mice for Huntington’s Disease
by: Cristine de Paula Nascimento-Castro, et al.
Published: (2018-01-01)

Single-Cell Suspension Methodology Favors Survival and Vascularization of Fetal Striatal Grafts in the YAC128 Mouse Model of Huntington's Disease
by: G. Cisbani, et al.
Published: (2014-10-01)

Anti-semaphorin 4D immunotherapy ameliorates neuropathology and some cognitive impairment in the YAC128 mouse model of Huntington disease
by: Amber L. Southwell, et al.
Published: (2015-04-01)

Wild-type huntingtin ameliorates striatal neuronal atrophy but does not prevent other abnormalities in the YAC128 mouse model of Huntington disease
by: Leavitt Blair R, et al.
Published: (2006-12-01)

Mice lacking caspase-2 are protected from behavioral changes, but not pathology, in the YAC128 model of Huntington disease
by: Bissada Nagat, et al.
Published: (2011-08-01)

Partial rescue of some features of Huntington Disease in the genetic absence of caspase-6 in YAC128 mice
by: Bibiana K.Y. Wong, et al.
Published: (2015-04-01)

DAPK1 Promotes Extrasynaptic GluN2B Phosphorylation and Striatal Spine Instability in the YAC128 Mouse Model of Huntington Disease
by: Mandi E. Schmidt, et al.
Published: (2020-11-01)

Altering cortical input unmasks synaptic phenotypes in the YAC128 cortico-striatal co-culture model of Huntington disease
by: Mandi E. Schmidt, et al.
Published: (2018-06-01)

Solid Lipid Curcumin Particles Protect Medium Spiny Neuronal Morphology, and Reduce Learning and Memory Deficits in the YAC128 Mouse Model of Huntington’s Disease
by: Abeer Gharaibeh, et al.
Published: (2020-12-01)

In Vivo Dopamine Efflux is Decreased in Striatum of both Fragment (R6/2) and Full-length (YAC128) Transgenic Mouse Models of Huntington’s Disease
by: Joshua W Callahan, et al.
Published: (2011-07-01)

Induced Pluripotent Stem Cell-Derived Neural Stem Cell Transplantations Reduced Behavioral Deficits and Ameliorated Neuropathological Changes in YAC128 Mouse Model of Huntington's Disease
by: Abeer Al-Gharaibeh, et al.
Published: (2017-11-01)

AAV-dominant negative tumor necrosis factor (DN-TNF) gene transfer to the striatum does not rescue medium spiny neurons in the YAC128 mouse model of Huntington's disease.
by: Laura Taylor Alto, et al.
Published: (2014-01-01)

Striatal neuronal apoptosis is preferentially enhanced by NMDA receptor activation in YAC transgenic mouse model of Huntington disease
by: Jacqueline Shehadeh, et al.
Published: (2006-02-01)

P38 MAPK is involved in enhanced NMDA receptor-dependent excitotoxicity in YAC transgenic mouse model of Huntington disease
by: Jing Fan, et al.
Published: (2012-03-01)

Huntingtin-Associated Protein 1A Regulates Store-Operated Calcium Entry in Medium Spiny Neurons From Transgenic YAC128 Mice, a Model of Huntington’s Disease
by: Magdalena Czeredys, et al.
Published: (2018-10-01)